PDS Biotechnology Corporation

NasdaqCM:PDSB

Sector

🏥 Health Care

Industries

💉 Vaccines

🧬 Biotechnology

🔬 Clinical Trials

Location

United States

Market Cap

USD 66.52 M

Share Price

USD 1.41

Avg Daily Volume

599,014

Change (1 day)

-2.76%

Change (1 year)

-53.16%

Change (YTD)

-13.50%

PDS Biotechnology Corporation Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending March 31, 2025

PDS Biotechnology Corporation Free Cash Flow Per Share is NA for the Trailing 12 Months (TTM) ending March 31, 2025. Free cash flow per share is the free cash flow generated per share. Indicates investment potential based on cash flow generation.

PDS Biotechnology Corporation Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending March 31, 2024 was USD -0.95, a -15.40% change year over year.
PDS Biotechnology Corporation Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -1.12, a 97.61% change year over year.
PDS Biotechnology Corporation Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -0.57.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Free Cash Flow Per Share	Dividend Per Share	Debt to Equity Ratio	Quick Ratio

NasdaqCM: PDSB

PDS Biotechnology Corporation

CEO	Dr. Frank K. Bedu-Addo Ph.D.
IPO Date	Sept. 30, 2015
Location	United States
Headquarters	25B Vreeland Road
Employees	24
Sector	🏥 Health Care
Industries Vaccines 🧬 Biotechnology 🔬 Clinical Trials

Description

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.